O	0	6	Impact
O	7	9	of
O	10	11	a
O	12	20	tailored
O	21	25	oral
B-intervention	26	33	vitamin
I-intervention	34	35	D
I-intervention	36	51	supplementation
I-intervention	52	59	regimen
O	60	62	on
O	63	68	serum
O	69	71	25
O	71	72	-
O	72	86	hydroxyvitamin
O	87	88	D
O	89	95	levels
O	96	98	in
O	99	104	early
O	105	111	breast
O	112	118	cancer
O	119	127	patients
O	127	128	:
O	129	130	a
O	131	141	randomized
O	142	147	phase
O	148	151	III
O	152	157	study
O	157	158	.

O	159	160	A
O	161	169	minority
O	170	172	of
O	173	178	early
O	179	185	breast
O	186	192	cancer
O	193	194	(
O	194	197	EBC
O	197	198	)
O	199	207	patients
O	208	215	treated
O	216	220	with
O	221	229	adjuvant
O	230	232	or
O	233	244	neoadjuvant
O	245	257	chemotherapy
O	258	262	have
O	263	273	sufficient
O	274	282	baseline
O	283	290	vitamin
O	291	292	D
O	293	294	(
O	294	298	vitD
O	298	299	)
O	300	305	level
O	305	306	.

O	307	311	This
O	312	322	randomized
O	323	328	phase
O	329	332	III
O	333	338	study
O	339	347	assessed
O	348	351	the
O	352	358	safety
O	359	362	and
O	363	371	efficacy
O	372	374	of
O	375	376	a
O	377	385	tailored
O	385	386	,
O	387	391	high
O	391	392	-
O	392	396	dose
O	396	397	,
O	398	402	oral
O	403	407	vitD
O	408	423	supplementation
O	424	426	in
O	427	436	restoring
O	437	438	a
O	439	445	normal
O	446	448	25
O	448	449	-
O	449	456	hydroxy
O	457	461	vitD
O	462	463	(
O	463	468	25OHD
O	468	469	)
O	470	475	level
O	476	478	in
O	479	483	this
O	484	494	population
O	494	495	.

O	496	508	Participants
O	509	517	received
O	518	519	a
B-control	520	521	6
I-control	521	522	-
I-control	522	527	month
I-control	528	540	conventional
I-control	541	542	(
I-control	542	543	C
I-control	543	544	)
I-control	545	549	vitD
I-control	550	553	and
I-control	554	561	calcium
I-control	562	577	supplementation
O	578	580	or
O	581	582	a
B-intervention	583	584	6
I-intervention	584	585	-
I-intervention	585	590	month
I-intervention	591	595	high
I-intervention	595	596	-
I-intervention	596	600	dose
I-intervention	601	605	oral
I-intervention	606	610	vitD
O	611	618	regimen
O	619	627	tailored
O	628	630	on
O	631	634	the
O	635	645	deficiency
O	646	647	(
O	647	648	T
O	648	649	)
O	650	653	and
O	654	655	a
O	656	668	conventional
O	669	676	calcium
O	677	692	supplementation
O	692	693	.

O	694	697	The
O	698	705	primary
O	706	709	end
O	710	715	point
O	716	719	was
O	720	723	the
B-outcome-Measure	724	725	6
I-outcome-Measure	725	726	-
I-outcome-Measure	726	731	month
I-outcome-Measure	732	742	percentage
I-outcome-Measure	743	745	of
I-outcome-Measure	746	751	25OHD
I-outcome-Measure	752	757	serum
I-outcome-Measure	758	763	level
I-outcome-Measure	764	777	normalization
O	777	778	.

O	779	780	A
O	781	786	total
O	787	789	of
B-total-participants	790	793	215
O	794	802	patients
O	803	812	including
O	813	816	197
O	817	825	patients
O	826	830	with
O	831	835	vitD
O	836	846	deficiency
O	847	851	were
O	852	861	recruited
O	861	862	,
O	863	866	and
B-total-participants	867	870	195
O	871	879	patients
O	880	884	were
O	885	895	randomized
O	896	897	(
O	897	898	T
O	898	899	,
B-intervention-participants	900	903	100
O	903	904	;
O	905	906	C
O	906	907	,
B-control-participants	908	910	95
O	910	911	)
O	911	912	.

B-outcome	913	923	Compliance
I-outcome	924	926	to
I-outcome	927	930	the
I-outcome	931	936	daily
I-outcome	937	941	oral
I-outcome	942	957	supplementation
O	958	961	was
B-cv-bin-percent	962	964	68
I-cv-bin-percent	964	965	.
I-cv-bin-percent	965	966	4
I-cv-bin-percent	966	967	%
O	968	971	and
B-iv-bin-percent	972	974	67
I-iv-bin-percent	974	975	%
O	976	978	in
O	979	982	the
O	983	984	C
O	985	988	and
O	989	990	T
O	991	995	arms
O	995	996	,
O	997	1009	respectively
O	1009	1010	.

B-outcome	1011	1024	Discontinuous
I-outcome	1025	1029	high
I-outcome	1029	1030	-
I-outcome	1030	1034	dose
I-outcome	1035	1039	vitD
I-outcome	1040	1050	compliance
O	1051	1059	appeared
O	1060	1066	higher
O	1067	1069	in
O	1070	1073	the
O	1074	1075	T
O	1076	1079	arm
O	1080	1081	(
B-iv-bin-percent	1081	1083	77
I-iv-bin-percent	1083	1084	%
O	1084	1085	)
O	1085	1086	.

O	1087	1089	At
O	1090	1091	6
O	1092	1098	months
O	1098	1099	,
O	1100	1104	more
O	1105	1113	patients
O	1114	1123	presented
O	1124	1128	with
O	1129	1130	a
B-outcome	1131	1141	normalized
I-outcome	1142	1146	vitD
I-outcome	1147	1152	level
O	1153	1155	in
O	1156	1159	the
O	1160	1161	T
O	1162	1165	arm
O	1166	1167	(
B-iv-bin-percent	1167	1169	30
I-iv-bin-percent	1169	1170	%
O	1171	1177	versus
B-cv-bin-percent	1178	1180	12
I-cv-bin-percent	1180	1181	.
I-cv-bin-percent	1181	1182	6
I-cv-bin-percent	1182	1183	%
O	1183	1184	;
O	1185	1186	P
O	1187	1188	=
O	1189	1190	0
O	1190	1191	.
O	1191	1194	003
O	1194	1195	)
O	1195	1196	.

O	1197	1212	Supplementation
O	1213	1216	was
B-outcome	1217	1221	well
I-outcome	1222	1231	tolerated
O	1231	1232	,
O	1233	1236	and
O	1237	1239	no
O	1240	1251	significant
O	1252	1262	difference
O	1263	1265	in
O	1266	1269	the
O	1270	1279	treatment
O	1279	1280	-
O	1280	1287	related
O	1288	1296	toxicity
O	1297	1304	between
O	1305	1308	the
O	1309	1312	two
O	1313	1317	arms
O	1318	1321	was
O	1322	1330	reported
O	1330	1331	.

B-cv-bin-percent	1332	1337	Fifty
I-cv-bin-percent	1337	1338	-
I-cv-bin-percent	1338	1341	two
O	1342	1350	patients
O	1351	1358	without
O	1359	1363	vitD
O	1364	1377	normalization
O	1378	1382	from
O	1383	1386	the
O	1387	1388	C
O	1389	1392	arm
B-outcome	1393	1401	switched
I-outcome	1402	1404	to
I-outcome	1405	1408	the
I-outcome	1409	1410	T
I-outcome	1411	1414	arm
O	1415	1420	after
O	1421	1422	6
O	1423	1429	months
O	1429	1430	.

O	1431	1433	At
O	1434	1436	12
O	1437	1443	months
O	1443	1444	,
O	1445	1447	44
O	1447	1448	%
O	1449	1451	of
O	1452	1457	these
O	1458	1466	patients
B-outcome	1467	1475	achieved
I-outcome	1476	1480	vitD
I-outcome	1481	1494	normalization
O	1494	1495	.

O	1496	1497	A
O	1498	1506	tailored
O	1507	1511	high
O	1511	1512	-
O	1512	1516	dose
O	1517	1521	oral
O	1522	1526	vitD
O	1527	1542	supplementation
O	1543	1549	safely
O	1550	1556	allows
O	1557	1558	a
O	1559	1565	higher
O	1566	1576	percentage
O	1577	1579	of
O	1580	1583	the
O	1584	1589	serum
O	1590	1595	25OHD
O	1596	1601	level
O	1602	1615	normalization
O	1616	1624	compared
O	1625	1629	with
O	1630	1631	a
O	1632	1644	conventional
O	1645	1652	regimen
O	1653	1655	in
O	1656	1668	chemotherapy
O	1668	1669	-
O	1669	1676	treated
O	1677	1680	EBC
O	1681	1689	patients
O	1689	1690	.

O	1691	1693	As
O	1694	1704	compliance
O	1705	1707	to
O	1708	1709	a
O	1710	1715	daily
O	1716	1720	oral
O	1721	1736	supplementation
O	1737	1744	remains
O	1745	1749	poor
O	1750	1752	in
O	1753	1757	this
O	1758	1765	setting
O	1765	1766	,
O	1767	1769	an
O	1770	1780	adaptation
O	1781	1783	of
O	1784	1787	the
O	1788	1797	treatment
O	1798	1806	schedule
O	1807	1809	is
O	1810	1819	warranted
O	1819	1820	.

O	1821	1832	NCT01480869
O	1832	1833	.
